Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development

B Investment supports continued Phase 1 clinical advancement of SynKIR™-110 in advanced solid tumors and SynKIR™-310 in B cell non-Hodgkin lymphoma Initial clinical data from…
posteditor
posteditor
Articles: 16137

Other News